Navigation Links
Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
Date:9/13/2011

ASHBURN, Va., Sept. 13, 2011 /PRNewswire/ -- Innocoll, Inc. announced top-line results from its phase 2 clinical trial investigating XaraColl for the management of post-operative pain and also announced it has received a "Notice of Allowability" for its XaraColl patent application in the United States.

The clinical trial was a U.S. multi-centered, double-blind, 2-way study comparing the analgesic effect of XaraColl versus placebo in patients undergoing herniorrhaphy via open laparotomy. Patients receiving XaraColl demonstrated a statistically significant reduction in the total use of opioid medication through 24 and 48 hours post-surgery as well as a statistically significant increase in the time before patients took any opioid medication.

The "Notice of Allowability" received from the United States Patent and Trademark Office for U.S. patent application #20080241245 covers products comprising any amino amide or amino ester anesthetic in a collagen matrix intended for the provision of local analgesia or anesthesia.

Dr. Michael Myers, Innocoll's President and CEO commented, "We are pleased to announce two such important milestones for XaraColl and for the company.  XaraColl is an important commercial asset for Innocoll and these latest developments serve as a positive endorsement of its progress to date."

About XaraColl:

XaraColl is a biodegradable and fully resorbable collagen/bupivacaine matrix formulated and manufactured using Innocoll's proprietary collagen-based drug delivery technology, CollaRx. This technology achieves a high concentration of drug at the target tissue, while maintaining low systemic levels.  XaraColl is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery.  The product is available in several different strengths, and is designed such that multiple units can be used per patient, for
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
2. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
3. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
(Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
... Janssen Pharmaceuticals, Inc. today announced the results ... ER (tapentadol) extended-release tablets were significantly more effective ... with chronic moderate to severe, painful diabetic peripheral ... at the 31st Annual Scientific Meeting of the ...
Cached Medicine Technology:Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:11/22/2014)... November 23, 2014 Today, Dylan Queen, ... new collection of wedding dresses; the business offers a ... related accessories for ladies worldwide, allowing them to create ... of the company, this new collection of chic wedding ... Moreover, they are offered at discounted rates now. Dylan ...
(Date:11/22/2014)... 22, 2014 Discount-Dress.com is an ... the firm is to increase the company’s online market share ... new selection of bridesmaid dresses and announced a bridesmaid dress ... valid until Dec. 30, 2014. All the dresses from this ... , In fact, Discount-Dress.com is very good at manufacturing ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 "My friend ... pain caused by the machine," said an inventor from ... had to go back a second time because the ... idea." , She developed the patent-pending MAMO EASY to ... cancer. The design saves the patient from the pain ...
(Date:11/22/2014)... The wide variety and complexity of foods served at ... food allergies, an expert warns. "Every person is ... allergies that it can be really difficult to avoid ... of allergy and clinical immunology at Wake Forest Baptist ... "If you know you have food allergies, caution should ...
(Date:11/22/2014)... This month has been a historical time for Angeldress.co.uk, ... positive reviews from some renowned review websites. Recently, the company ... a new selection of wonderful sexy wedding dresses to its ... shipping and up to an 80% discount on any order ... the most suitable dress at Angeldress.co.uk, which has garnered a ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2
... metalloproteinase 1 and vitamin D synthesis may determine the ... ,The researchers analysed genetic variations in 312 people, just ... replacement in the 10 years following surgery. ... 'aseptic loosening,' which describes a condition in which the ...
... March 14 (IANS) India Wednesday launched a major initiative ... NGO// in Tamil Nadu planning a usage study in ... with the Hindustan Latex Ltd and the National Aids ... to provide female condoms at just Rs.3 to NGOs ...
... move could force pharmaceutical companies into a reformulation drive ... flu products// that do not contain the restricted ingredients. ... letter seeking opinion on the proposed restrictions, which would ... reduction in pack size by the end of 2007. ...
... pressure could certainly be an indicator of one’s happiness. Researchers ... between a nation's overall happiness and its citizens' blood pressure ... people from across the European countries. ,These people were asked ... hypertension (high blood pressure) and so on. ,While ...
... Brasilia – Svelte models have lent their charm in the many ... enviable trend//, a recent survey has painted a different picture of ... thought to be and the men drink far too much. Nearly ... over weight category, the survey revealed. ,Sao Paulo, the ...
... discovered a new type of cells, which they say appear ... ,The medical team led by Jian-Xin Gao at Ohio ... or pCSCs, that can either remain benign or become malignant, ... cells are very complex. They have properties of normal and ...
Cached Medicine News:Health News:India to Market Female Condoms 2Health News:UK to Pull Pseudoephedrine 2Health News:UK to Pull Pseudoephedrine 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... is designed for the repair of abdominal ... that has two distinct sides. One ... a layer of sodium hyaluronate and carboxymethylcellulose ... This coated side is bioresorbable, providing a ...
... Human explant studies have confirmed ... for maximum clinical performance in hernia ... Atriums thinner and less dense hernia ... less rigid repair. Since 1994, when ...
Medicine Products: